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Trends in the incidence of classic Kaposi’s sarcoma in the Jewish population in Israel for the period between 1960 and 1998 were
analysed. World standardised incidence rates of 20.7 and 7.5 per million among men and women, respectively, were calculated. The
highest incidence rates were displayed by men originated from Africa and by Asian-born women.
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Kaposi’s sarcoma (KS) is a multifocal vascular tumour that
predominantly presents as a multipigmented sarcoma of the skin.
Classic Kaposi’s sarcoma (CKS) is known as a clinicoepidemiolo-
gical indolent variant of the disease primarily affecting the elderly
(Sarid et al, 1999; Antman and Chang, 2000). Kaposi’s sarcoma-
associated herpesvirus (KSHV), also known as human herpesvirus
8 (HHV-8), is believed to be a major causative factor for all clinical
variants of KS (Chang et al, 1994; Ablashi et al, 2002). In general,
the seroprevalence rates of KSHV in different geographical regions
correlate with the incidence rates of CKS (Gao et al, 1996;
Chatlynne and Ablashi, 1999; Schulz, 1999; Antman and Chang,
2000). Yet, genetic and/or environmental cofactors affecting the
risk of CKS after KSHV infection probably play an important role,
and thus may modify the relationship between the seroprevalence
of KSHV and incidence of KS (Ariyoshi et al, 1998; Goedert et al,
2002; Grossman et al, 2002).
The objective of the present study was to investigate the trends
in the incidence of CKS in Israeli Jews between 1960 and 1998. The
analysis of the trends of CKS in Jews living in Israel is unique,
Israel being one of the countries with the highest incidence of CKS
in the world, and a migration center for Jews from various
countries of origin.
METHODS
All KS cases reported to the population-based Israel Cancer
Registry (ICR) between 1960 and 1998 were identified under skin
cancer and sarcoma codes according to the International
Classification of Diseases for Oncology Version 2 (ICD-O-2)
morphology code 9140 (World Health Organization, 1979). ICR
covers the entire Israeli population, and data quality is estimated
to be high (Steinitz, 1989; Parkin et al, 1997). All recorded
diagnoses were manually checked for registration accuracy; no
misclassifications were found. No cases were reported on post
mortem. KS cases that were diagnosed among immigrants before
their arrival to Israel, among the Arab population, and in
nonresidents were excluded. To identify the AIDS-associated KS,
the ICR file was linked with the national HIV-seropositive and
AIDS registries; 60 HIV-seropositive KS cases were excluded. The
registry of HIV and AIDS cases in Israel is incomplete, due to the
mandatory identification requirement. Yet, we believe that the
majority of AIDS-KS cases are diagnosed and reported following
their application for medical care.
ICR is linked to the Israel Population Registry, and receives
information of date and country of birth, gender, immigration and
mortality. Therefore, data retrieved from the ICR included these
records, date of CKS diagnosis and topographical ICD-O codes.
Using population data from the Population Registry at the
National Bureau of Statistics (Central Bureau of Statistics, 1960–
1998), age-, sex- and country of origin-specific incidence rates
were calculated, as were age-standardised incidence rates, using
the world standard population as a reference. Linear regression
multivariate analysis was used to model incidence rates with
respect to calendar period, age at diagnosis, gender and country or
continent of origin (Breslow and Day, 1987).
RESULTS
A total of 2107 cases of CKS (1475 men, 632 women, M/F¼2.33)
were registered in the entire Israeli Jewish population, during the
39-year study period (1960–1998).
Overall, the age-standardised incidence rates of CKS (7s.d.) in
the Jewish population were 20.7 (79.3) per million among men
and 7.5 (73.4) per million in women. The gender incidence ratio
was 2.76 (RR¼2.76 (20.7/7.5); 95% CI 1.57–3.95) and was rather Received 1 May 2003; revised 28 July 2003; accepted 11 August 2003
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number of CKS cases for both genders combined for consecutive
10-year periods of diagnosis was 81 (3.8% of total cases) between
1960 and 1969, steeply increased to 396 cases between 1970 and
1979 (18.8%), followed by 574 cases (27.2%) between 1980 and
1989. A second substantial increase was observed during the
period between 1990 and 1998, with 1056 new cases (50.1%). No
significant trend in incidence was observed during other periods
(Table 1).
A significant trend of increase in the mean age at diagnosis, in
both genders, was evident. This might be due to the extended
lifespan. In men, the mean age (7s.d.) increased from 64.9
(713.2) to 69.5 (713.9) during the period between 1960 and 1998
(Po0.01). In women, there was an even more pronounced increase
in the mean age at diagnosis (7s.d.), from 51.9 (718.1) to 73.5
(712.7) (Po0.01). The age-specific rates increased from 10.2 per
million in men and 2.5 per million in women in the age group of
35–44, to 300.8 per million in men and 119.2 per million in women
in the age group of 75 or more. Among the age group of 0–24, the
rates per million were 0.6 and 0.2 in males and females,
respectively, with no cases recorded below 5 years of age
(Table 2). The substantial increase with age in the age-specific
rates of CKS cases is consistent with other reports (Cottoni et al,
1996; Hjalgrim et al, 1996; Brenner et al, 2002).
Immigrants born in Asia, Africa, Europe and America exhibited
a strong increase in incidence rates during the late 1960s and the
early 1970s, and during the early 1990s. Israel-born Jews
demonstrated a similar increase in incidence during the late
1960s and the early 1970s but failed to show the second strong
increase during the 1990s.
Analysis of CKS incidence rates by continent of origin revealed
highly significant (Po0.01) differences in incidence rates (Table 3).
Overall, the Jews born in Africa demonstrated the highest
incidence rates in men and the second for women, followed by
high rates in Asian-born Jews. Few cases were registered for Jews
originating from America.
Standardised ratio and relative risks (RRs) for specific
representative countries of origin could be calculated only for
the period between 1980 and 1994, with Jews born in Israel taken
as reference (Table 4). Prior to and after 1980–1994, the data
received from the Population Registry were gathered as groups of
countries that could not be separated. In men, the highest
incidence rate was observed among immigrants from Romania.
In women, the highest incidence rate was observed among
immigrants from Iraq.
DISCUSSION
The present study, based on 2107 registered CKS cases among
Jewish residents of Israel, has found an age-standardised incidence
rate of CKS (7s.d.) of 20.7 (79.3) per million among men and 7.5
(73.4) per million in women. Similar rates of CKS were reported,
for much narrower calendar periods, from Sardinia (Cottoni et al,
1996) and Sicily (Geddes et al, 1994). A rather constant gender
ratio of 2.33 was found, which is in agreement with previous
population-based surveys (Biggar et al., 1984; Dictor and Attewell,
1988; Grulich et al., 1992; Geddes et al, 1994).
Here we report higher rates compared with those previously
reported for the Israeli Jewish population for the period 1961–
1989 (16.9 per million in men and 6.3 per million in women), in
which a total of 1098 cases of CKS were analysed (Iscovich et al,
1998). The higher rates described in our study can be explained by
the addition of 1009 new CKS cases and by the vast changes in the
Jewish population composition with the mass migration of
approximately 1000000 new immigrants from the Former Soviet
Union (FSU) during the late 1980s and the 1990s.
The present study demonstrates two steep rises in incidence. A
similar pattern of increase in incidence rates during the early 1970s
was described (Hjalgrim et al, 1996; Dictor and Attewell, 1988).
Improved registration is likely to have played a certain role, but it
cannot be the sole explanation for this finding. Differences in
immigration patterns in Israel may provide another explanation.
During the 1950s through the late 1960s, there were large
immigration waves from Iraq and North African countries, and
during the late 1960s and early 1970s there were large immigration
waves from Eastern Europe.
The increase in incidence rates during the early 1990s can be
explained by the fact that CKS is a slowly developing disease, and
similar to other chronic diseases, migrants are more likely to be
diagnosed with such disorders, as a result of entering a new health
system. An additional explanation for this increase might be the
aging of the population that arrived with the large immigration
waves to Israel during the 1950s and the 1960s. Moreover, this
could also be explained by the massive immigration wave from the
FSU. Interestingly, the majority of the newly diagnosed cases of
CKS between 1990 and 1998 were among Jews of East European
origin, whereas CKS incidence rates between 1990 and 1998 were
higher for Jews originating from Africa and Asia, despite the much
lower number of newly diagnosed cases among them.
The significant difference in incidence rates by countries of
origin suggests an important role for geographical differences in
the prevalence of KSHV (Chatlynne and Ablashi, 1999; Schulz,
1999). Variation in KSHV seroprevalence among Israeli popula-
tions was found to be strongly associated with the country of birth
(Davidovici et al, 2001). The highest rates of anti-KSHV antibodies
were found in those born in North African countries, and the
lowest rates were found in those born in Europe or North America
Table 1 Number of cases and age-standardised rates of classic Kaposi’s
sarcoma in Israeli Jews between 1960 and 1998
Men Women
Period
No. of
cases ASR
Crude
rate
No. of
cases ASR
Crude
rate
1960–1964 23 5.1 4.47 8 2.2 1.59
1965–1969 39 6.5 6.54 11 1.9 1.88
1970–1974 117 16.7 17.31 44 6.0 6.54
1975–1979 163 19.3 21.41 72 7.8 9.42
1980–1984 171 17.6 20.05 74 6.7 8.8
1985–1989 236 21.6 26.44 93 6.8 10.31
1990–1994 384 30.4 37.45 161 9.9 15.38
1995–1998 342 29.7 37.61 169 10.7 17.99
1960–1998 1475 20.7 23.76 632 7.5 10.11
ASR: age-standardised rate (per 1000000).
Table 2 Age-standardised incidence rates (based on world standard
population) of classic Kaposi’s sarcoma among Israeli Jews by gender and
patient age group between 1960 and 1998
Men Women
Age group
(years)
No. of
cases
Rate per
million
No. of
cases
Rate per
million
0–24 17 0.6 6 0.2
25–34 45 5.1 17 1.9
35–44 75 10.2 19 2.5
45–54 110 18.9 32 5.2
55–64 261 53.9 85 16.3
65–74 417 121.4 203 51.8
X75 550 300.8 270 119.2
Total 1475 20.7
a 632 7.5
a
aAge-standardised rate (per 1000000).
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particularly high incidence of CKS observed in our study among
North African Jewish immigrants in Israel.
In summary, our study supports an important role for the
country of origin, which, together with environmental conditions,
is likely to be of importance in influencing the exposure of
individuals to KSHV, and may also be implicated in establishing
the risk for the development of CKS. Furthermore, it could be
possible that the seroprevalence rates of KSHV and CKS incidence
rates among the various Israeli subpopulations reflect the situation
in the countries of origin, and thus our population may serve as an
‘indicator population’. Still, since CKS that was originally
described in Jews of eastern European descent is also highly
prevalent in Jews from Asia and Africa, it may suggest that
infection with KSHV had been relatively more prevalent among
Jews before the Diaspora of Jewish people that started more than
2500 years ago.
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Table 3 Age-standardised incidence rates of CKS among Israeli Jews by geographical origin, calendar period of diagnosis and gender
Israeli-born Asian-born African-born European- and American-born
Men Women Men Women Men Women Men Women
1960–1964
N o . 2 1 2250 1 3 5
ASR 7.3 5.6 2.3 1.9 11.4 0 4.5 1.9
1965–1969
N o . 1 1 3071 2 8 9
ASR 4.5 0.2 2.8 0 11.2 0.8 6.9 2.3
1970–1974
No. 14 5 20 7 15 4 67 28
ASR 32.8 7.2 16.6 5.8 20.6 4.8 18.6 6.4
1975–1979
No. 12 6 26 13 35 14 90 39
ASR 20.3 6.7 17.6 7.8 36.5 13.3 16.8 6.2
1980–1984
No. 16 3 30 8 27 15 97 47
ASR 20.1 2.7 18.9 4.9 21.5 11.6 14.3 6.5
1985–1989
No. 25 7 48 19 48 19 114 48
ASR 21.5 9.0 26.6 9.5 35.0 12.6 16.7 7.2
1990–1994
No. 48 7 63 24 94 29 179 100
ASR 19.0 4.5 54.0 10.2 56.0 15.1 22.7 11.8
1995–1998
No. 37 8 60 31 90 32 154 98
ASR 25.7 5.4 39.0 48.4 60.7 18.6 20.7 8.7
1960–1998
No. 155 38 252 104 321 114 742 374
ASR 18.9 5.2 22.2 12.6 31.6 11.0 15.1 6.4
ASR: age-standardised rate.
Table 4 Relative risk of classic Kaposi’s sarcoma by selected countries of origin and gender, 1980–1994
Men Women Relative risk
Country No. of cases ASR No. of cases ASR Men Women
Israel 89 2.02 17 0.54 1 1
FSU 75 1.48 53 0.95 0.7(0.94–2.341) 1.8(0.83–4.43)
Poland 147 2.20 57 0.77 1.1(0.96–3.16) 1.4(0.92–3.72)
Yemen 32 2.83 6 0.42 1.4(0.92–3.72) 0.8(0.95–2.55)
Iraq 70 3.62 35 1.67 1.8(0.83–4.43) 3.1(0.35–6.55)
Morocco 104 4.35 41 1.6 2.1(0.74–4.94) 3.0(0.39–6.39)
Romania 93 4.51 42 0.7 2.2(0.71–5.11) 1.3(0.93–3.53)
ASR: age-standardised rate; FSU: Former Soviet Union.
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